Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor-An Opportunity for Cancer Treatment

Tumor necrosis factor receptor 2 (TNFR2) is expressed on some tumor cells, such as myeloma, Hodgkin lymphoma, colon cancer and ovarian cancer, as well as immunosuppressive cells. There is increasingly evidence that TNFR2 expression in cancer microenvironment has significant implications in cancer pr...

Full description

Saved in:
Bibliographic Details
Published in:Cells (Basel, Switzerland) Switzerland), 2019-12, Vol.9 (1), p.33
Main Authors: Al-Hatamleh, Mohammad A I, E A R, Engku Nur Syafirah, Boer, Jennifer C, Ferji, Khalid, Six, Jean-Luc, Chen, Xin, Elkord, Eyad, Plebanski, Magdalena, Mohamud, Rohimah
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Cancer therapies
Chemical Sciences
Colon cancer
Demethylation
Deoxyribonucleic acid
DNA
DNA Demethylation - drug effects
DNA methylation
Drug Synergism
Epigenesis, Genetic - drug effects
Epigenetics
Hodgkin's lymphoma
Humans
Immunotherapy
Kinases
Malignancy
Metastases
Microenvironments
Myeloma
Nanomedicine
Nanotechnology
Neoplasms - drug therapy
Neoplasms - genetics
Neoplasms - metabolism
Organic chemistry
Ovarian cancer
Polymers
Receptors, Tumor Necrosis Factor, Type II - antagonists & inhibitors
Signal Transduction - drug effects
Tumor cells
Tumor Microenvironment
Tumor necrosis factor receptor 2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor necrosis factor receptor 2 (TNFR2) is expressed on some tumor cells, such as myeloma, Hodgkin lymphoma, colon cancer and ovarian cancer, as well as immunosuppressive cells. There is increasingly evidence that TNFR2 expression in cancer microenvironment has significant implications in cancer progression, metastasis and immune evasion. Although nanomedicine has been extensively studied as a carrier of cancer immunotherapeutic agents, no study to date has investigated TNFR2-targeting nanomedicine in cancer treatment. From an epigenetic perspective, previous studies indicate that DNA demethylation might be responsible for high expressions of TNFR2 in cancer models. This perspective review discusses a novel therapeutic strategy based on nanomedicine that has the capacity to target TNFR2 along with inhibition of DNA demethylation. This approach may maximize the anti-cancer potential of nanomedicine-based immunotherapy and, consequently, markedly improve the outcomes of the management of patients with malignancy.
ISSN:2073-4409
2073-4409
DOI:10.3390/cells9010033